

## Literatuurlijst SEIN publicaties 2025

### *Inclusief Impact Factor*

Deze lijst bevat alle publicaties die terug te vinden zijn in pubmed met een SEIN affiliatie, geordend op alfabetische volgorde van de eerste auteur.

1. **Anguelova GV**. Optimizing external validation of deep neural networks for interictal discharge detection. *Epilepsia*. 2025 Jul;66(7):2596–2597. doi: 10.1111/epi.18412. Epub 2025 May 23. PMID: 40407068 (Impact Factor 6,6)
2. van Arnhem MML, van Teeseling HC, **van den Berg L**, Braun KPJ, Jansen FE. Intelligence outcomes in 17 patients with developmental and/or epileptic encephalopathy with spike-wave activation in sleep ((D)EE-SWAS) after remission of SWAS. *Epilepsy Behav*. 2025 Dec;173:110806. doi: 10.1016/j.yebeh.2025.110806. Epub 2025 Nov 4. PMID: 41192048 (Impact Factor 2,3)
3. Asogwa OA, Dirven L, Walbert T, Armstrong TS, Arons D, van den Bent MJ, Blakeley J, Coomans MB, Brown PD, Bulbeck H, Chang SM, Coens C, Gilbert MR, Grant R, Jalali R, Koekkoek JAF, Panda PK, Leach D, Leeper H, Mendoza T, Nayak L, Oliver K, **Reijneveld JC**, Le Rhun E, Rubinstein L, Taylor JW, Weller M, Wen PY, Taphoorn MJB. Establishing the content validity of patient-reported outcome measures used in neuro-oncology based on the WHO ICF framework: Part of the RANO-PRO initiative. *Neuro Oncol*. 2025 Oct 14;27(9):2399–2414. doi: 10.1093/neuonc/noaf108. PMID: 40293144 (Impact Factor 16,4)
4. Becking BE, Jonkman REG, **Stumpel DJPM**, van Merkesteyn JPR, Van den Akker-Van Marle ME. Validation of the Dutch sleep-related breathing disorder scale from the pediatric sleep questionnaire: a diagnostic accuracy study using polysomnography. *Sleep Breath*. 2025 Nov 28;29(6):370. doi: 10.1007/s11325-025-03539-1. PMID: 41313503 (Impact Factor 2,1)
5. Benditt DG, Fedorowski A, ..., **Thijs R**, Ungar A, Van Rossum IA. 'Transient immediate orthostatic hypotension' is preferable to 'initial' orthostatic hypotension. *Auton Neurosci*. 2025 Aug;260:103288. doi: 10.1016/j.autneu.2025.103288. Epub 2025 May 16 (Impact Factor 3,2)
6. den Besten-Bertholee D, **Wegner I**, Touw DJ, Horst PGJ, Mian P. Lamotrigine Use in Lactating Women: Passage Into Breast Milk and Infant Exposure. *Ther Drug Monit*. 2025 Jun 1;47(3):317–319. doi: 10.1097/FTD.0000000000001299. Epub 2024 Dec 17. PMID: 39688255 (Impact Factor 2,8)
7. **Bijlenga D**, **De Boer J**, **Fronczek R**, Tiemensma J, **Lammers G J**. Patient-reported outcome measure for central disorders of hypersomnolence (PROM-CDH): development and validation. *Sleep Med*. 2025 Sep;133:106589. doi: 10.1016/j.sleep.2025.106589. Epub 2025 May 19 (Impact Factor 3,8)
8. Boele F, **Jensen C**, Madigan Johnson G, **Lammers-Spijker A**, **Altinbas A**, **van den Berg L**, **Broekman-Labinac K**, **Fronczek R**, **Schuur M**, **Vonk G**, **Zijlmans M**.

- Visser G, Reijneveld J.** Health-related quality of life and unmet needs of people with epilepsy and their family caregivers: A systematic scoping review. *Epilepsy Behav.* 2025 Oct;171:110601. doi: 10.1016/j.yebeh.2025.110601. Epub 2025 Jul 24. (Impact Factor 2,3)
9. van den Boom MA, Gregg NM, Valencia GO, Lundstrom BN, Miller KJ, **van Blooijis D**, Huiskamp GJM, Leijten FSS, Worrell GA, Hermes D. ER-detect: a pipeline for robust detection of early evoked responses in BIDS-iEEG electrical stimulation data. *J Neurosci Methods.* 2025 Jun;418:110389. doi: 10.1016/j.jneumeth.2025.110389. Epub 2025 Feb 12 (Impact Factor 2,7)
10. **Bosch AT, Sander JW, Thijs RD.** Correction: Antiseizure Medications and Sudden Unexpected Death in Epilepsy: An Updated Review. *CNS Drugs.* 2025 May;39(5):525. doi: 10.1007/s40263-025-01176-6.PMID: 40120031 (Impact Factor 7,4)
11. **Bosch AT**, Leijten FSS, **Thijs RD.** How often do caregivers attend their child when a seizure detection device alerts for a nocturnal major motor seizure? *Epilepsia.* 2025 Oct;66(10):3810–3821. doi: 10.1111/epi.18534. Epub 2025 Aug 6 (Impact Factor 6,6)
12. Bot L, van Mill JG, Smarius LJCA, Hoogendoorn AW, Storosum BWC, Vinkers CH, Jacobs GE, **Lammers GJ**, Heller HM, Colen-de Koning JCA, van der Vlugt JJB, Oudijn MS, van Noorden MS, Bet PM, **Fronczek R**, van der Heijden HS, Lange SMM, van der Werf YD, van Exel ER. Sodium Oxybate as a Potential New Treatment for Catatonia in Patients With Depression, Bipolar Disorder, or a Psychotic Disorder: Protocol for a Randomized Controlled Trial. *JMIR Res Protoc.* 2025 Jul 24;14:e68356. doi: 10.2196/68356.PMID: 40705436 (Impact Factor 1,4)
13. **Broekman-Labinac K**, Aben L, **Thijs RD, Smeding HMM**, de Jongh A, van der Hiele K. A preliminary efficacy study of eye movement desensitisation and reprocessing therapy in reducing epilepsy-related anxiety. *Epilepsy Behav.* 2025 Oct;171:110493. doi: 10.1016/j.yebeh.2025.110493. Epub 2025 May 24 (Impact Factor 2,3)
14. Brouwers TMJ, Çobanoğlu ÜG, Geers D, Rietdijk WJR, Gommers L, Bogers S, **Lammers GJ**, van der Horst GTJ, Chaves I, GeurtsvanKessel CH, Koch BCP, de Vries RD, van Baarle D, van der Kuy HM, Lammers-van der Holst HM. The effect of sleep and shift work on the primary immune response to messenger RNA-based COVID-19 vaccination. *J Sleep Res.* 2025 Aug;34(4):e14431. doi: 10.1111/jsr.14431. Epub 2024 Dec 10.PMID: 39658344 (Impact Factor 3,4)
15. Bruijn NRA, Huessler EM, MaassenVanDenBrink A, **Fronczek R**, Diener HC, Ferrari MD, Al-Hassany L. Placebo Response in Acute and Prophylactic Treatment of Migraine: A Systematic Review and Meta-Analysis Covering 36 Years of Research. *Neurol Clin.* 2026 Feb;44(1):23–45. doi: 10.1016/j.ncl.2025.08.011. Epub 2025 Oct 15.PMID: 41232995 (Impact Factor 2,4)
16. Caramanna I, Klein M, van den Bent M, Idbaih A, Taphoorn MJB, Dirven L, Gorlia T, **Reijneveld JC**; EORTC Quality of Life Group. Neurocognitive impairment and patient-proxy agreement on health-related quality of life

- evaluations in recurrent high-grade glioma patients. *Qual Life Res.* 2025 Aug;34(8):2405–2418. doi: 10.1007/s11136-025-03984-1. Epub 2025 Jun 5 (Impact Factor 3,3)
17. Coffeng SM, van der Horn HJ, Out ML, **Metting Z**, van der Jagt RMD, van der Naalt J. Determinants of long-term health-related quality of life in paediatric traumatic brain injury. *Eur J Paediatr Neurol.* 2025 Nov;59:11–17. doi: 10.1016/j.ejpn.2025.09.003. Epub 2025 Sep 24 (Impact Factor 2,3)
  18. Coppola G, Arruda MA, Ashina M, Barloese M, Belin AC, Bottiroli S, Chowdhury D, De Icco R, Di Lorenzo C, Di Stefano G, Edvinsson JCA, Evers S, Ferraro S, **Fronczek R**, ..., Wang Y, Wijeratne T, Martelletti P. Hallmarks of primary headache: part 3 – cluster headache. *J Headache Pain.* 2025 Oct 2;26(1):196. doi: 10.1186/s10194-025-02145-6.PMID: 41039211 (Impact Factor 7,3)
  19. Darkwa EK, Asiamah S, Awini E, Sottie C, Godi A, Williams JE, Akpalu A, Cross JH, **Sander JW**, Sen A, Newton CR, Danso-Appiah A, Adjei P. Translation, adaptation and validation of an epilepsy screening instrument in two Ghanaian languages. *PLoS One.* 2025 Jan 17;20(1):e0303735. doi: 10.1371/journal.pone.0303735. eCollection 2025.PMID: 39823446 (Impact Factor 3,3)
  20. Dauvilliers Y, Plazzi G, Mignot E, **Lammers GJ**, Del Río Villegas R, Khatami R, Taniguchi M, Abraham A, Hang Y, Kadali H, Lambertson M, Sheikh S, Stukalin E, Neuwirth R, Swick TJ, Tanaka S, von Hehn C, von Rosenstiel P, Wang H, Cai A, Naylor M, Olsson T. Oveporexton, an Oral Orexin Receptor 2-Selective Agonist, in Narcolepsy Type 1. *N Engl J Med.* 2025 May 15;392(19):1905–1916. doi: 10.1056/NEJMoa2405847.PMID: 40367374 Clinical Trial (Impact Factor 94,3)
  21. Dekker J, Schot R, Aldinger KA, ..., **Aronica E**, Anink J, Rogers SL, Slep KC, Doherty D, Dobyns WB, Mancini GMS. A clinical and genotype-phenotype analysis of MACF1 variants. *Am J Hum Genet.* 2025 Oct 2;112(10):2363–2380. doi: 10.1016/j.ajhg.2025.08.010. Epub 2025 Sep 8 (Impact Factor 8,1)
  22. **Dietze CS**, van Gorp TC, **Meppelink AM**, Jansen FE, LaFrance WC Jr, van der Salm SMA, **Zijlmans M**. Functional seizures: Scoping review of classifications and proposal of novel three-axis model. *Epilepsy Behav.* 2025 May 26;171:110484. doi: 10.1016/j.yebeh.2025.110484. Online ahead of print.PMID: 40424815 (Impact Factor 2,3)
  23. **Dietze CS**, van Waart-Houtman D, **Meppelink AM**, **Bourez-Swart M**, van der Palen J, **Zijlmans M**, van der Salm SMA. Diagnostic Value of Bereitschaftspotential in People With Functional Seizures. *J Clin Neurophysiol.* 2025 May 1;42(4):331–335. doi: 10.1097/WNP.0000000000001123. Epub 2024 Oct 3.PMID: 39358826 (Impact Factor 2,3)
  24. Dimakopoulos V, Gotman J, Klimes P, von Ellenrieder N, Tan SB, Smith G, Gliske SV, Maltseva M, Manalo MK, Pail M, Brazdil M, van Blooijis D, van 't Klooster MA, Johnson S, Laboy S, Ledergerber D, Imbach L, Papadelis C, Sperling MR, **Zijlmans M**, Cimbalnik J, Jacobs J, Stacey WC, Frauscher B, Sarnthein J. Multicentre analysis of seizure outcome predicted by removal of

- high-frequency oscillations. *Brain*. 2025 May 13;148(5):1769–1777. doi: 10.1093/brain/awae361.PMID: 39530262 (Impact Factor 3,6)
25. van Dijk JG, **Gagaouzova BS**, de Jong JSY, van Rossum IA, van Houwelingen MJ, Kerkhof FI, Reijntjes RH, Paton JFR, de Lange FJ, **Thijs RD**. Pathophysiological aspects of carotid sinus massage. *Europace*. 2025 Mar 28;27(4):euaf047. doi: 10.1093/europace/euaf047.PMID: 40103329 (Impact Factor 7,9)
26. **Donjacour CEHM**, Gool JK, Schoffelen PF, Wouters L, Overeem S, **Lammers GJ**, Pijl H, Westerterp KR. Measuring energy expenditure in narcolepsy using doubly labeled water and respiration chamber calorimetry. *Sleep*. 2025 Apr 11;48(4):zsae263. doi: 10.1093/sleep/zsae263.PMID: 39546380 (Impact Factor 5,3)
27. Douw L, **Reijneveld JC**, Mandal AS. Multiscale network perspectives on glioma: from tumour biology to symptoms, survival and treatment. *Nat Rev Neurol*. 2025 Dec 5. doi: 10.1038/s41582-025-01171-x. Online ahead of print.PMID: 41350399 Review (Impact Factor 28,2)
28. Duta I, Kariuki SM, Ngugi AK, Mwesige AK, Masanja H, Mwanga DM, Owusu-Agyei S, Wagner R, Cross JH, **Sander JW**, Newton CR, Sen A, Jones GD. Evaluating the generalisability of region-naive machine learning algorithms for the identification of epilepsy in low-resource settings. *PLOS Digit Health*. 2025 Feb 12;4(2):e0000491. doi: 10.1371/journal.pdig.0000491. eCollection 2025 Feb.PMID: 39937713 (Impact Factor unknown)
29. Ferrazzini L, Schmidt M, Zhang Z, Khatami R, Dauvilliers Y, Barateau L, Mayer G, Pizza F, Plazzi G, Gool JK, **Fronczek R**, **Lammers GJ**, Del Rio-Villegas R, Peraita-Adrados R, Partinen M, Overeem S, Sonka K, Santamaria J, Heinzer R, Canellas F, da Silva AM, Högl B, Veauthier C, Wierzbicka A, Feketeova E, Buskova J, Lecendreux M, Miano S, Kallweit U, Heidbreder A, Bassetti CLA, van der Meer J. Daytime sleepiness and BMI exhibit gender and age differences in patients with central disorders of hypersomnolence. *J Sleep Res*. 2025 Jun;34(3):e14365. doi: 10.1111/jsr.14365. Epub 2024 Oct 21.PMID: 39428908 (Impact Factor 3,4)
30. Fritz L, Zaloumis E, Zwinkels H, **Reijneveld JC**, Vos MJ, Pasma HRW, Dirven L, Koekkoek JAF, Taphoorn MJB. End-of-life care in patients with glioblastoma after early advance care planning. *Neurooncol Pract*. 2025 May 22;12(5):821–829. doi: 10.1093/nop/npaf050. eCollection 2025 Oct.PMID: 41080190 (Impact Factor 2,4)
31. **Gagaouzova BS**, van der Stam A, Johansson M, Van Rossum IA, Kerkhof FI, Reijntjes R, van Houwelingen M, **Thijs RD**, Fedorowski A, van Dijk JG. The relative contribution of hemodynamic parameters to blood pressure decrease in classical orthostatic hypotension. *J Hypertens*. 2025 Mar 1;43(3):436–444. doi: 10.1097/HJH.0000000000003832. Epub 2024 Sep 18.PMID: 39440925 (Impact Factor 3,3)
32. **Gagaouzova BS**, van Rossum IA, **van Hoey Smith J**, de Lange FJ, **Thijs RD**, van Dijk JG. Novel insights regarding haemodynamics in focal seizures. *Epilepsy Res*. 2025 Feb;210:107513. doi: 10.1016/j.eplepsyres.2025.107513. Epub 2025 Jan 23.PMID: 39979000 (Impact Factor 2)

33. Gamper EM, King MT, Shaw JW, Schiel A, Kalo Z, van der Weijst L, Cella D, **Reijneveld JC**, Pe M. Shifting perspectives: a reflection on cancer-specific quality-of-life metrics in cancer care economics. *Lancet Oncol.* 2025 May;26(5):545–547. doi: 10.1016/S1470-2045(25)00066-X.PMID: 40318641 (Impact Factor 41,6)
34. **Gefferie SR**, **van Nieuw Amerongen AR**, **Visser GH**, **Zijlmans M**, Tolner EA, van de Ruit M, van den Maagdenberg AMJM, **Thijs RD**. EEG Spectral Exponents and Visual Chirp Responses Mirror Anti-Seizure Medication Load in Refractory Focal Epilepsy. *Ann Clin Transl Neurol.* 2025 Jun;12(6):1265–1275. doi: 10.1002/acn3.70045. Epub 2025 Apr 21.PMID: 40256879 (Impact Factor 4,4)
35. **van Griethuysen R**, **van Asch CJJ**, Otte WM, **Lamberink H**, **Sander JW**, **Bourez-Swart MD**, de Jong L, Colon AJ, Braun KPJ; NeedtoStop Study Group. Antiseizure medication reduction in long-term video-electroencephalographic monitoring for presurgical evaluation: A multicenter safety and efficacy analysis. *Epilepsia.* 2025 Jul 25. doi: 10.1111/epi.18572. Online ahead of print.PMID: 40709605 (Impact Factor 6,6)
36. Gool JK, Schinkelshoek MS, **Fronczek R**. How (long) did you sleep last night? *Sleep.* 2025 Oct 13;48(10):zsaf172. doi: 10.1093/sleep/zsaf172.PMID: 40576963 (Impact Factor 5,3)
37. Guo J, Wang Z, van Klink N, Schaft E, Sun D, van der Salm S, van 't Klooster M, **Zijlmans M**. Multi-montage visualization of interictal epileptic events in high-density intraoperative electrocorticography. *Clin Neurophysiol Pract.* 2025 Dec 20;11:13–15. doi: 10.1016/j.cnp.2025.12.006. eCollection 2026.PMID: 41537129 (Impact Factor 2,0)
38. Haglund A, Zuber V, ... , **Aronica E**, Matthews PM, Thom M, Sisodiya SM, Srivastava PK, Malhotra D, Bryois J, Bottolo L, Johnson MR. Cell state-dependent allelic effects and contextual Mendelian randomization analysis for human brain phenotypes. *Nat Genet.* 2025 Feb;57(2):358–368. doi: 10.1038/s41588-024-02050-9. Epub 2025 Jan 10.PMID: 39794547 (Impact Factor 36,6)
39. van der Ham M, **Bijlenga D**, Molenaar N, Starreveld DEJ, Böhmer MN, Wettstein R, Dumont G, Beekman ATF, Kooij S. The Effects of Sleep Treatment on Symptoms of ADHD, Sleep Quality, Fatigue, and Depressive Symptoms in Adults. *J Atten Disord.* 2025 Oct 27:10870547251379103. doi: 10.1177/10870547251379103. Epub ahead of print. PMID: 41140200. (Impact Factor 2,2)
40. Hao N, Abdulaziz AT, Lu L, Chen Y, Li T, Liu J, Lin X, Chen L, Hao X, Li J, Wu X, O'Brien TJ, **Sander JW**, Zhou D. Seizure control and pregnancy outcomes in Chinese women with epilepsy: A prospective multicenter cohort study. *Epilepsia.* 2025 May;66(5):1573–1584. doi: 10.1111/epi.18294. Epub 2025 Feb 11.PMID: 39931893 (Impact Factor 6,6)
41. **van Heese EM**, **Gool JK**, **Lammers GJ**, van der Werf YD, van Osch MJP, **Fronczek R**, Hirschler L. MRI-based surrogates of brain clearance in narcolepsy type 1. *J Sleep Res.* 2025 Dec;34(6):e14479. doi: 10.1111/jsr.14479. Epub 2025 Feb 18 (Impact Factor 3,4)

42. **Helling RM**, van Dijk JP, Bauer PR, **Thijs RD**, **Sander JW**, Zwarts M, **Visser GH**. Cortical Excitability Before and After Long-Term Perampanel Treatment for Epilepsy. *Ann Clin Transl Neurol*. 2025 Jun;12(6):1256–1264. doi: 10.1002/acn3.70044. Epub 2025 Apr 17. PMID: 40244706 (Impact Factor 4,4)
43. **van der Hoeven AE**, **Fronczek R**, **Bijlenga D**, **Hadra S**, Ridder C, Henneman M, Maas JA, Goedemans-de Graaf SA, **Lammers GJ**, van Westerloo DJ, **Schinkelshoek MS**. Dream Experiences During Intensive Care Unit Stay: Occurrence, Content, Vividness and Associated Factors. *Nurs Crit Care*. 2025 Jul;30(4):e70106. doi: 10.1111/nicc.70106. PMID: 40603708 (Impact Factor 3,0)
44. van Hout L, Borgio AD, Grun N, **Schuur M**, Broen MPG, Westerman BA, Bartelink I, Vandertop WP, Lissenberg-Witte BI, Kouwenhoven MCM. Severe temozolomide-induced thrombocytopenia is linked to increased healthcare utilization in glioblastoma and disproportionately impacts female patients. *Neurooncol Pract*. 2025 Jan 22;12(4):678–690. doi: 10.1093/nop/npaf013. eCollection 2025 Aug. PMID: 40814424 (Impact Factor 2,4)
45. Jansen JJ, Scheurink J, **Balvers T**, **Fronczek R**, Mulleners WM. Beyond coincidence: a case series on the clinical course of coinciding cluster headache and short-lasting unilateral neuralgiform headache attacks. *Pain Rep*. 2025 Apr 28;10(3):e1271. doi: 10.1097/PR9.0000000000001271. eCollection 2025 Jun. PMID: 40303899 (Impact Factor 3,4)
46. Jareonsettasin P, Ji JS, Zhou X, Ding D, **Sander JW**; SdHIELD (Social determinants of Health In EpiLeptic Disorders) Research Group. The role of air pollution in epilepsy: a better understanding is needed. *Arq Neuropsiquiatr*. 2025 Jun;83(6):1–12. doi: 10.1055/s-0045-1809663. Epub 2025 Jul 2. PMID: 40602803 (Impact Factor 1,0)
47. Jareonsettasin P, **Sander JW**. The Role of Social Determinants of Health in Childhood Epilepsy. *Turk Arch Pediatr*. 2025 Jan 2;60(1):13–21. doi: 10.5152/TurkArchPediatr.2025.24271. PMID: 39803913 (Impact Factor 1,3)
48. **Jelsma SB**, **Zijlmans M**, **Heijink IB**, Hoefnagels FWA, Raemaekers M, Otte WM, van Klink NEC, **van Blooijis D**. Structural and effective brain connectivity in focal **epilepsy**. *Neuroimage Rep*. 2025 Jun 27;5(3):100274. doi: 10.1016/j.ynirp.2025.100274. eCollection 2025 Sep. PMID: 41050944 (Impact Factor unknown)
49. Johansson M, **Gagaouzova BS**, van Rossum IA, **Thijs RD**, Hamrefors V, van Dijk JG, Fedorowski A. Etiology and hemodynamic patterns of orthostatic hypotension in a tertiary syncope unit. *Europace*. 2025 May 7;27(5):euaf017. doi: 10.1093/europace/euaf017 (Impact Factor 6,3)
50. Karpuzov S, **Kalitzin S**, Georgieva O, Trifonov A, Stoyanov T, Petkov G. Automated Remote Detection of Falls Using Direct Reconstruction of Optical Flow Principal Motion Parameters. *Sensors* 2025, Volume 25, Issue 18, 5678 (Impact Factor 3,4)
51. **Lammers GJ**, Plazzi G, Mignot E, Pizza F, Dauvilliers Y, Barateau L, Maruff P, Scammell TE, Latzman RD, Naylor M, Olsson T, Stukalin E, Tanaka S, Volfson D, Khachadourian V, Harel BT. Effects of Oveporexton, an Orexin Receptor 2-

- Selective Agonist, on Cognition in Narcolepsy Type 1: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Neurol.* 2025 Dec 8:e254825. doi: 10.1001/jamaneurol.2025.4825. Online ahead of print.PMID: 41359331 (Impact Factor 20,4)
52. Lemke JR, Eoli A, Krey I, Popp B, Strehlow V, Wittekind DA, Vuorinen AL, Aldhalaan HM, Baer S, de Saint Martin A, Hammer TB, Herman I, Hornemann F, Ingebrigtsen T, Lederer D, Lesca G, Marafie D, Mathot M, Rosenfeld JA, Møller RS, **Schelhaas HJ**, Stillman C, Orsini A, Patel AD, Piard J, Veggiotti P, Vlaskamp DRM, Weckhuysen S, Traynelis SF, Benke TA, Heyne HO, Syrbe S. GRIN2A null variants confer a high risk for early-onset schizophrenia and other mental disorders and potentially enable precision therapy. *Mol Psychiatry.* 2025 Oct 14. doi: 10.1038/s41380-025-03279-4. Online ahead of print.PMID: 41087560 (Impact Factor 9,6)
53. Le Rhun E, Sain D, Erridge SC, Reardon DA, Minniti G, Roth P, Wick W, Nabors B, Sampson J, Mason W, Cloughesy T, **Reijneveld JC**, Stupp R, Preusser M, Gorlia T, Weller M. Proton Pump Inhibitor Use and Survival in Patients With Newly Diagnosed Glioblastoma. *JAMA Netw Open.* 2025 Nov 3;8(11):e2545578. doi: 10.1001/jamanetworkopen.2025.45578.PMID: 41288972 (Impact Factor 10,5)
54. Leu C, Avbersek A, Stevelink R, Custodio HM, Chen S, Speed D, Bennett CA, Jonsson L, Unnsteinsdóttir U, Jorgensen AL, Cavalleri GL, Delanty N, Craig JJ, Depondt C, Johnson MR, Koeleman BPC, Hassanin E, Omidvar ME, Krause R, Lerche H, Marson AG, O'Brien TJ, **Sander JW**, Sills GJ, Striano P, Zara F, Stefansson H, Stefansson K, May P, Neale BM, Lal D, Berkovic SF; Epi25 Collaborative; EpiPGX Consortium; Sisodiya SM. Genome-wide association meta-analyses of drug-resistant epilepsy. *EBioMedicine.* 2025 May;115:105675. doi: 10.1016/j.ebiom.2025.105675. Epub 2025 Apr 15.PMID: 40240269 (Impact Factor 9,7)
55. **van Loo-Flier H**, **Dietze CS**, **Meppelink AM**. Tailored provocation in functional seizures, a pilot study. *Epilepsy Res.* 2025 Nov 13;219:107692. doi: 10.1016/j.eplepsyres.2025.107692. Online ahead of print.PMID: 41242157 (Impact Factor 2,0)
56. Magili PF, Massawe IS, Mushi VP, Bhwana DK, Matuja W, Colebunders R, Cross H, **Sander JW**, Sen A, Newton CR, Mahone S, Mmbando BP. "The traditional healer said, 'I had a genie that scared me in my eyes, and that is why I fall': An ethnographic study in Mahenge, Tanzania. *Epilepsy Behav.* 2025 Sep;170:110463. doi: 10.1016/j.yebeh.2025.110463. Epub 2025 May 17.PMID: 40382998 (Impact Factor 2,3)
57. Naber WC, **Fronczek R**. Through the eyes of Janus: Remission and disease activity in cluster headache. *Cephalalgia.* 2025 Sep;45(9):3331024251368258. doi: 10.1177/03331024251368258. Epub 2025 Sep 13.PMID: 40944403 (Impact Factor 5,0)
58. Naber WC, van Tilborg PJ, Brandt RB, Jansen JJ, Wilbrink LA, Mulleners WM, Kurt E, Leen W, Huygen FJPM, **Bijlenga D**, **Fronczek R**. Quality of life changes in cluster headache: Convergent validity, responsiveness, and interpretability

- of the Cluster Headache Quality of Life scale as a patient-reported outcome measure. *Headache*. 2025 Nov 13. doi: 10.1111/head.15083. Online ahead of print. PMID: 41230804 (Impact Factor 5,4)
59. Naber W, van Tilborg P, Zuidgeest A, Wilbrink L, Mulleners W, Brandt R, **Fronczek R**. Exploration of Prolonged Remission and the Natural Course of Cluster Headache: An Interview-Based Cohort Study. *Neurology*. 2025 Jul;105(1):e213795. doi: 10.1212/WNL.00000000000213795. Epub 2025 Jun 13. PMID: 40513059 (Impact Factor 7,7)
60. Neligan A, Vivekananda U, **Sander JW**. Focal, generalised epilepsy or both? *Pract Neurol*. 2025 Jul 14;25(4):349–351. doi: 10.1136/pn-2024-004290. PMID: 39500562 (Impact Factor 2,4)
61. Noorlag L, Fonteyn EMR, **Zijlmans M**. No one is too young to show high frequency oscillations on scalp EEG. *Clin Neurophysiol*. 2025 Aug;176:2110795. doi: 10.1016/j.clinph.2025.2110795. Epub 2025 Jun 16. (Impact Factor 3,7)
62. van Norden SJ, Kho KH, **Meppelink AM**, **Ardesch JJ**, Tjepkema-Cloostermans MC, van Putten MJAM. Ultra-long-term subcutaneous EEG recordings in ten epilepsy patients: Experiences and circadian rhythms in epileptiform discharges. *Epilepsy Behav Rep*. 2025 May 20;31:100781. doi: 10.1016/j.ebr.2025.100781. eCollection 2025 Sep. PMID: 40502850 (Impact Factor 1,8)
63. Nordentoft S, **Boele F**, Guldager R, Larsen A, Hertler C, Sherwood P, Pappot H, Mathiesen T, Piil K. Group-based interventions for caregivers to patients diagnosed with a brain tumor: A systematic review. *Neurooncol Pract*. 2025 Jul 18;12(6):983–997. doi: 10.1093/nop/npaf070. eCollection 2025 Dec. PMID: 41458934 (Impact Factor 2,4)
64. Panicker JN, Fanciulli A, Skoric MK, Kaplan T, Aleksovska K, Adamec I, Averbeck MA, Campese N, Guaraldi P, Leys F, Moreno-Palacios J, Simeoni S, Stankovic I, Wright S, Batla A, Blok B, Hentzen C, Hilz MJ, Kessler TM, Madersbacher H, Nair KR, Nair KPS, Pakzad M, Traon AP, Peryer G, Przydacz M, Sakakibara R, Saraf U, Smith M, Struhal W, **Thijs RD**, Tudor KI, Tutaj M, Vodušek DB, Wenning G, Habek M. European Academy of Neurology (EAN)/European Federation of Autonomic Societies (EFAS)/International Neuro-Urology Society (INUS) Guidelines for Practising Neurologists on the Assessment and Treatment of Neurogenic Urinary and Sexual Symptoms (NEUROGED Guidelines). *Eur J Neurol*. 2025 Apr;32(4):e70119. doi: 10.1111/ene.70119. PMID: 40208234 (Impact Factor 4,9)
65. Pe M, Voltz-Girolt C, Bell J, Bhatnagar V, Bogaerts J, Booth C, Burgos JG, Cappelleri JC, Coens C, Demolis P, Enzmann H, Giesinger JM, Gilbert A, Groenvold M, Kluetz P, Piccinin C, Postmus D, Quinten C, Ryll B, Sasseville M, Schlichting M, Schuerer H, Schiel A, Shaw JW, Smith AW, Tezuka S, Torre C, van der Graaf WTA, Wieseler B, Wittenbecher F, **Reijneveld JC**, Mol P. Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC

- workshop. Lancet Oncol. 2025 Jun;26(6):687–690. doi: 10.1016/S1470–2045(25)00150–0. Epub 2025 Apr 14. PMID: 40245904 (Impact Factor 41,6)
66. Pevernagie DA, Arnardottir ES, Bruni O, Hartley S, **Lammers GJ**, Paunio T, Riemann D, Riha RL. Sleep Medicine–What's in a Name? J Sleep Res. 2025 Oct;34(5):e70150. doi: 10.1111/jsr.70150. Epub 2025 Jul 19 (Impact Factor 3,4)
67. Piccinin C, Aaronson NK, Bjordal K, Coens C, Darlington AS, Efficace F, Fitzsimmons D, Giesinger JM, Gilbert A, Holzner B, Kuliś D, Nolte S, Pe M, Petersen MA, **Reijneveld JC**, Singer S, Sprangers MAG, Taphoorn MJB, Tomaszewski KA, van de Poll–Franse L, Velikova G, Wheelwright S, Groenvold M; EORTC Quality of Life Group. Flexibility in patient–reported outcome and health–related quality of life measurement: The EORTC Quality of Life Group measurement strategy. Eur J Cancer. 2025 May 2;220:115392. doi: 10.1016/j.ejca.2025.115392. Epub 2025 Mar 29. PMID: 40194468 (Impact Factor 7,6)
68. Prins EM, Pijpers A, Verbeek N, Darweesh SKL, Geerlings AD, Meinders MJ, Bloem BR, **van Dijk KD**, Dommershuijsen LJ. The impact of REM–sleep behavior disorder on people with Parkinson's disease and their partners. NPJ Parkinsons Dis. 2025 May 17;11(1):130. doi: 10.1038/s41531–025–00986–1. PMID: 40382383 (Impact Factor 6,7)
69. Ribeiro–Rodrigues L, Fonseca–Gomes J, Paulo SL, Viais R, Ribeiro FF, Miranda–Loureço C, Mouro FM, Belo RF, Ferreira CB, Tanqueiro SR, Ferreira–Manso M, Umemori J, Castrén E, Paiva VH, Sebastião AM, **Aronica E**, Campos AR, Bentes C, Xapelli S, Diógenes MJ. Cleavage of the TrkB–FL receptor during epileptogenesis: insights from a kainic acid–induced model of epilepsy and human samples. Pharmacol Res. 2025 May;215:107707. doi: 10.1016/j.phrs.2025.107707. Epub 2025 Mar 19 (Impact Factor 9,1)
70. Salim HS, Thabit A, **Hoogteijling S**, van 't Klooster MA, van Walsum T, **Zijlmans M**, Benmahdjoub M. Super–resolution for localizing electrode grids as small, deformable objects during epilepsy surgery using augmented reality headsets. Int J Comput Assist Radiol Surg. 2025 Nov;20(11):2319–2327. doi: 10.1007/s11548–025–03401–5. Epub 2025 Jun 19. (Impact Factor 2,3)
71. Schaft EV, Sun D, **Hoogteijling S**, Wang Z, Leijten FSS, van Eijnden P, Ramsey NF, Robe P, van 't Klooster MA, **Zijlmans M**; RESPECT Database Group. Implementing intraoperative high–density electrocorticography during epilepsy surgery. Epilepsia. 2025 May;66(5):1447–1461. doi: 10.1111/epi.18302. Epub 2025 Feb 11. (Impact Factor 6,6)
72. Scheepens JCC, **Boele FW**, Koekkoek JAF. Patient–proxy agreement on health–related quality of life assessment in cancer patients. Curr Opin Oncol. 2025 Nov 1;37(6):603–610. doi: 10.1097/CCO.0000000000001189. Epub 2025 Sep 22. PMID: 40990180 Review (Impact Factor 2,8)
73. Schubert KM, Zieglgänsberger D, Biciato G, Abraira L, Santamarina E, Álvarez–Sabín J, Ferreira–Atuesta C, Katan M, Sinka L, Terziev R, Deligas N, Erdélyi–Canavese B, Felbecker A, Siebel P, Winklehner M, von Oertzen TJ, Wagner JN, Gigli GL, Nilo A, Janes F, Merlino G, Valente M, Zafra–Sierra MP,

- Mayor-Romero LC, Conrad J, Evers S, Alet M, Fukuma K, Ihara M, Landau B, Lochner P, Roell F, Brigo F, Bentes C, Peralta AR, Pinho E Melo T, **Keezer MR**, Duncan JS, **Sander JW**, Tettenborn B, Koepf MJ, Galovic M. Association of the Timing and Type of Acute Symptomatic Seizures With Poststroke Epilepsy and Mortality. *Stroke*. 2025 Jul;56(7):1748–1757. doi: 10.1161/STROKEAHA.124.050045. Epub 2025 Apr 24 (Impact Factor 7,8)
74. **Shahbakhti M**, **Bosch AT**, Long X, van Dijk JP, **Thijs RD**. Characterizing vascular tone in nocturnal major motor seizures using wearable photoplethysmography. *Seizure*. 2025 Dec 4;134:186–189. doi: 10.1016/j.seizure.2025.12.001. Online ahead of print.PMID: 41421303 (Impact Factor 2,7)
75. Shi J, Lu D, Wei P, Yang Y, Dong H, Jin L, **Sander JW**, Shan Y, Zhao G. Comparative Efficacy of Neuromodulatory Strategies for Drug-Resistant Epilepsy: A Systematic Review and Meta-Analysis. *World Neurosurg*. 2025 Jan;193:373–396. doi: 10.1016/j.wneu.2024.09.084. Epub 2024 Oct 16.PMID: 39321920 (Impact Factor 1,9)
76. **Shlobin NA**, Li J, **Sander JW**, Keezer MR, **Thijs RD**. Cardiac Conduction Delay for Sodium Channel Antagonist Antiseizure Medications: An Analysis of the Canadian Longitudinal Study on Aging. *Neurology*. 2025 Feb 25;104(4):e210302. doi: 10.1212/WNL.0000000000210302. Epub 2025 Feb 3.PMID: 39899787 (Impact Factor 8,7)
77. Silvani A, Bassetti C, Bradicich M, Dodel R, Ferini Strambi L, Hajak G, Hedner J, Heinzer R, Javaheri S, Jennum P, Kallweit U, Khatami R, **Lammers GJ**, Pepin JL, Pizza F, Plante DT, Plazzi G, Randerath W, Santamaria J, Schiza S, Sundelin T, Troxel W, Manconi M. Hypersomnolence in focus: a white paper of the 6th Think Tank World Sleep Forum. *Sleep Med*. 2025 Sep;133:106607. doi: 10.1016/j.sleep.2025.106607. Epub 2025 Jun 6.PMID: 40505170 (Impact Factor 3,8)
78. Specchio N, Di Micco V, **Aronica E**, Auvin S, Balestrini S, Brunklaus A, Gardella E, Scheper M, Taglialatela M, Trivisano M, Curatolo P. The epilepsy–autism phenotype associated with developmental and epileptic encephalopathies: New mechanism–based therapeutic options. *Epilepsia*. 2025 Apr;66(4):970–987. doi: 10.1111/epi.18209. Epub 2025 Feb 22 (Impact Factor 6,6)
79. Specchio N, Di Micco V, Scheper M, **Aronica E**, Curatolo P. Mechanistic strategies for secondary prevention of developmental and epileptic encephalopathy in children with tuberous sclerosis complex. *EBioMedicine*. 2025 Jun;116:105740. doi: 10.1016/j.ebiom.2025.105740. Epub 2025 May 13.PMID: 40367637 (Impact Factor 9,7)
80. van der Stam AH, **Gagaouzova BS**, Kerkhof FI, van Rossum IA, Shmueli S, Reijntjes RH, van Houwelingen MJ, **Thijs RD**, van Dijk JG. Haemodynamic determinants of supine hypertension in patients with classical orthostatic hypotension. *J Hypertens*. 2025 Oct 30. doi: 10.1097/HJH.0000000000004194. Online ahead of print.PMID: 41230726 (Impact Factor 3,3)

81. Tannock IF, Pe ML, Booth CM, Brundage M, Cherny NI, Coens C, Eisenhauer EA, Geissler J, Giesinger JM, Gyawali B, Oosting SF, Pond GR, **Reijneveld JC**, Soto-Perez-de-Celis E, Tregear M, van der Graaf WTA. Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer. *Lancet Oncol.* 2025 Sep;26(9):e499–e507. doi: 10.1016/S1470–2045(25)00288–8.PMID: 40907528 Review. (Impact Factor 41,6)
82. Ter Horst PGJ, Truong T, Mian P, **Wegner I**. Lacosamide concentration–dose (C/D) ratios during pregnancy: a case series. *Eur J Clin Pharmacol.* 2025 Dec 22;82(1):10. doi: 10.1007/s00228–025–03924–5 (Impact Factor 2,4).
83. Terman SW, Kalia N, Dugan M, Silva JM, **van Asch C**, Burke JF, Smith SN, O’Kula SS, Hill CE. Challenges in antiseizure medication discontinuation decisions: A qualitative study of clinicians who see patients with epilepsy. *Clin Neurol Neurosurg.* 2026 Jan;260:109242. doi: 10.1016/j.clineuro.2025.109242. Epub 2025 Nov 14.PMID: 41252903 (Impact Factor 1,8)
84. Terman SW, Kalia N, Kuster M, Dugan M, Silva JM, **Van Asch CJJ**, Burke JF, Grant AC, Jehi L, Smith SN, Hill CE, O’Kula SS. Clinician Feedback Regarding Novel Graphical Risk Prediction Tools for Antiseizure Medication Discontinuation: A Qualitative Study. *Neurol Clin Pract.* 2025 Dec;15(6):e200540. doi: 0.1212/CPJ.0000000000200540. Epub 2025 Oct 9. (Impact Factor 2,3)
85. Teuschl Y, Fanciulli A, Pavy–Le Traon A, Habek M, **Thijs RD**, Pavelic AR, Struhal W. Is the NASA Lean Test a suitable tool to diagnose cardiovascular autonomic disorders? *Clin Auton Res.* 2025 Jun;35(3):529–531. doi: 10.1007/s10286–024–01097–2. Epub 2025 Jan 9 2025 Jan 9. PMID: 39786620 (Impact Factor 4,4)
86. van Tilborg PJ, **Bosch AT**, **Thijs RD**, **Fronczek R**. The clinical effect of an implanted vagus nerve stimulator in a patient with chronic cluster headache and focal epilepsy – A case report. *Headache.* 2025 May 20. doi: 10.1111/head.14963. Online ahead of print.PMID: 40391549 (Impact Factor 5,4)
87. **Vael VEC**, **Bijlenga D**, van der Wel AA, Wiersma RG, Koers I, **Fronczek R**, **Lammers GJ**. Diagnostic value of nocturnal sleep–onset rapid eye movement sleep period for narcolepsy type 1 and 2 in a tertiary sleep centre. *Sleep Med.* 2025 Jun;130:36–42. doi: 10.1016/j.sleep.2025.03.019. Epub 2025 Mar 22 (Impact Factor 3,8)
88. **Vassallo P**, Choong E, Aícuá–Rapún I, Stampfli C, André P, Rossetti AO, Buclin T, Decosterd LA, Novy J. Is the salivary concentration of lamotrigine and levetiracetam associated with clinical outcome? *Epilepsy Behav.* 2025 Oct;171:110595. doi: 10.1016/j.yebeh.2025.110595. Epub 2025 Jul 21 (Impact Factor 2,3)
89. **Vassallo P**, Gursal V, Xiong W, Zhou D, de Tisi J, **Thijs RD**, Duncan JS, **Sander JW**. Temporal Trends in Hippocampal Sclerosis Surgery: An Observational

- Study From a Tertiary Epilepsy Centre. *Eur J Neurol*. 2025 Jan;32(1):e70041. doi: 10.1111/ene.70041.PMID: 39804171 (Impact Factor 4,9)
90. **Vassallo P**, Poole O, Guan X, Giampiccolo D, Marques E, Vivekananda U, Duncan JS, Diehl B. Switch-Off response to mid-cingulate cortex stimulation: a video case report. *Clin Neurophysiol Pract*. 2025 Nov 7;10:524-526. doi: 10.1016/j.cnp.2025.10.008. eCollection 2025.PMID: 41324025 (Impact Factor 2,0)
91. **Vassallo P**, **Sander JW**. Emptying the fridge syndrome: a case of nocturnal food craving associated with peak perampanel concentration. *Epilepsy Behav Rep*. 2025 Aug 10;32:100821. doi: 10.1016/j.ebr.2025.100821. eCollection 2025 Dec.PMID: 4083788 (Impact Factor 1,8)
92. **Vringer M**, **Bijlenga D**, **Zhou J**, Meijer OC, Vinkers CH, **Lammers GJ**, **Fronczek R**. Physiological and psychological stress reactivity in narcolepsy type 1. *Sleep*. 2025 Mar 11;48(3):zsae265. doi: 10.1093/sleep/zsae265.PMID: 39546396 (Impact Factor 5,3)
93. **Vringer M**, **de Boer J**, **Lammers GJ**, **Fronczek R**, **Bijlenga D**. Symptoms of central disorders of hypersomnolence during phases of female hormonal transitions: an explorative self-report study. *Sleep Med*. 2025 Aug;132:106588. doi: 10.1016/j.sleep.2025.106588. Epub 2025 May 15.PMID: 40393109 (Impact Factor 3,8)
94. **Vringer M**, Cronie M, Remmerswaal A, Klumpers LE, **Lammers GJ**, **Fronczek R**, Schinkelshoek MS. Cannabis Use in Central Disorders of Hypersomnolence in the Netherlands. *Med Cannabis Cannabinoids*. 2025 Sep 17;8(1):181-187. doi: 10.1159/000548416. (Impact Factor unknown)
95. Walger L, Bauer T, Kügler D, Schmitz MH, Schuch F, Arendt C, Baumgartner T, Birkenheier J, Borger V, Endler C, Grau F, Immanuel C, Kölle M, Kupczyk P, Lakghomi A, Mackert S, Neuhaus E, Nordsiek J, Odenthal AM, Dague KO, Ostermann L, Pukropski J, Racz A, von der Ropp K, Schmeel FC, Schrader F, Sitter A, Unruh-Pinheiro A, Voigt M, Vychopen M, von Wedel P, von Wrede R, Attenberger U, Vatter H, Philipsen A, Becker A, Reuter M, Hattingen E, **Sander JW**, Radbruch A, Surges R, Rüber T. A Quantitative Comparison Between Human and Artificial Intelligence in the Detection of Focal Cortical Dysplasia. *Invest Radiol*. 2025 Apr 1;60(4):253-259. doi: 10.1097/RLI.0000000000001125. Epub 2024 Oct 23.PMID: 39437019 (Impact Factor 7)
96. Wang Z, Guo J, Schaft E, **Hoogteijling S**, Ferrier CH, **Visser GH**, Sun D, Hoefnagels F, Inada T, van der Salm S, Huiskamp G, van Klink N, Van't Klooster M, **Zijlmans M**; RESPECT database study group. The optimal montage to mark interictal epileptiform discharges and high-frequency oscillations in intraoperative electrocorticography. *Clin Neurophysiol Pract*. 2025 Jul 1;10:246-255. doi: 10.1016/j.cnp.2025.06.007. eCollection 2025.PMID: 40687074 (Impact Factor 2,0)
97. Willmann J, Verhoeff JJC, Kaidar-Person O, Abrunhosa-Branquinho A, Clementel E, Corning C, Portik D, Souza L, **Reijneveld JC**, Dhermain F, Hurkmans C, Monti AF, Saez J, Mason WP, Weller M, Roth P, Andratschke N.

- Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the radiotherapy delineation benchmark case procedure. *Radiother Oncol.* 2025 Oct;211:111088. doi: 10.1016/j.radonc.2025.111088. Epub 2025 Aug 10. (Impact Factor 4,9)
98. Wolsink A, Cliteur MP, **van Asch CJ**, Boogaarts HD, Dammers R, Hannink G, Schreuder FHBM, Klijn CJM. Incidence, case fatality, and functional outcome of intracerebral haemorrhage, according to age, sex, and country income level: a systematic review and meta-analysis. *Lancet Reg Health Eur.* 2024 Dec 13;49:101180. doi: 10.1016/j.lanepe.2024.101180. eCollection 2025 Feb. PMID: 39759582 (Impact Factor 13,6)
99. Zhou X, Ding D, Wang W, Zhou D, **Sander JW**. Mortality of Epilepsy in Chinese Populations: A Comprehensive Review. *Neuroepidemiology.* 2025;59(4):391-404. doi: 10.1159/000540426. Epub 2024 Jul 29. PMID: 39074464 (Impact Factor 3,2)
100. **Zhou J**, Melzi S, Morel AL, Georges B, Scammell TE, **Lammers GJ**, **Fronczek R**, Peyron C. Corticotropin-Releasing Hormone (CRH) in Murine Narcolepsy: What Do Genetic and Immune Models Tell Us? *J Sleep Res.* 2025 Jul 24:e70151. doi: 10.1111/jsr.70151. Online ahead of print. PMID: 40707858 (Impact Factor 3,4)